Innovation is giving rise to incredible medical advances and the development of health care practices and services that are always better suited to people’s needs. The decisive shift we are taking toward the judicious use of biosimilar drugs is a good example of this.
Business Practice
CME/CE
Subscribe
BIOSIMILAR APPROVALS
- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Quebec Makes It Harder to Use Originator Biologics
Biosimilars were on formulary for years but nobody was using them, Canadian authorities explain as their reasons for dropping originators from approved lists.
Quebec has become the fourth Canadian province to implement a mandatory biosimilar switching program. With some exceptions, the province is switching to a policy of allowing only biosimilars, if available, on lists of approved biologics.
“Thus, depending on the option considered, patients who use a reference biological drug, for which one or more biosimilar drugs are registered, will have to switch to one of these by April 12, 2022, under the supervision of their doctor,” said Minister of Health and Social Services Christian Dubé in a statement.
Manufacturers of reference biologics “have been informed of this shift” and “discussions will take place with the main partners and associations of the health and social services network on this subject in the coming weeks,” the statement said.
The province anticipates US $83 million in annual savings by 2022. Officials said the move follows failure to achieve sufficient uptake of biosimilars in Quebec even though they have been recommended by the National Institute of Excellence in Health and Social Services and placed on drug formularies “for many years.”
“This situation generates a considerable additional cost for the general drug insurance plan because biosimilar drugs are significantly less expensive than reference drugs, with no difference in [quality of] therapy for patients," according to Dubé.
Canadian health authorities stressed that biosimilars are safe and effective, proven similar to originator brand drugs, and authorized by use by the public health authority Health Canada. In 1997, Quebec adopted a general prescription drug insurance plan that provides universal health coverage for all citizens of the province. The cost of this plan from 2019 to 2020 was $5.1 billion.
Health Canada has approved 36 biosimilars for 14 innovator products. There are 13 other biosimilar candidates under review, and these include 5 bevacizumabs and 2 adalimumabs, according to an analysis by Smart & Bigggar, an intellectual property law firm. Regulatory reviews of biosimilars in Canada generally take about a year, although some are considerably longer.
A Decisive Shift
“Innovation is giving rise to incredible medical advances and the development of health care practices and services that are always better suited to people’s needs. The decisive shift we are taking toward the judicious use of biosimilar drugs is a good example of this,” Dubé said.
Biosimilars Canada, a trade group representing biosimilar distributors and manufacturers, applauded the move.
“These savings will be reinvested into the health care system and will also improve access to innovative drug therapies,” the group said.
Under the policy, patients who are being treated with an originator biologic drug for which a biosimilar biologic drug is available will switch to a biosimilar under the supervision of their treating physician by April 12, 2022.
“Biosimilar switching policies are essential to ensuring the long-term sustainability of drug benefit plans and health care systems,” said Jim Keon, president of Biosimilars Canada.
Quebec follows British Columbia, Alberta, and New Brunswick in implementing the biosimilars plan. Biosimilars Canada indicated that residents of Quebec were 85% in favor of a switching policy according to a recent poll.
Read about the New Brunswick, Canada, switch to biosimilars here.
Read about Amgen Canada's launch of an adalimumab biosimilar here.
Related Videos
Related Content
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Article
Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023Podcast
On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Article
Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023Podcast
On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Article
Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Article
Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.
